/** Builds publication-ready HTML for Q2 2026 pharma insight articles. */

function link(href, text) {
  return `<a href="${href}">${text}</a>`;
}

function p(text) {
  return `<p>${text}</p>`;
}

function h2(id, text) {
  return `<h2 id="${id}">${text}</h2>`;
}

function h3(text) {
  return `<h3>${text}</h3>`;
}

function li(text) {
  return `<li>${text}</li>`;
}

/**
 * @param {import('../data/q2-2026-pharma-insights-topics.mjs').Q2_2026_TOPICS[0]} t
 */
export function buildQ2ArticleHtml(t) {
  const brandGeneric = `${t.brand} (${t.generic})`;
  const title = `${brandGeneric} ${t.actionType} Q2 2026: Commercial Strategy, Clinical Milestones, and GCC Market Access Impact`;
  const slugAnchor = (s) => s.toLowerCase().replace(/[^a-z0-9]+/g, '-').replace(/^-|-$/g, '');

  const competitorsList = t.competitors.map((c) => `<li><strong>${c}</strong></li>`).join('\n');

  return `<article>
<h1>${title}</h1>

${p(
  `${t.sponsor}’s ${t.actionType.toLowerCase()} for ${brandGeneric} on ${t.actionDate} is a material inflection point for ${t.therapeuticArea} commercial strategy. ${t.headline} For vice presidents of commercial operations, regional market access directors, and GCC business development leads, the decision window is not “whether this matters,” but how quickly evidence, regulatory reciprocity, and tender positioning can be synchronized before competitors compress price corridors and formulary slots.`,
)}

${p(
  `This BioNixus executive brief translates the global regulatory action into board-ready metrics, payer mechanics, and Saudi/UAE execution priorities. We anchor claims to documented development pathways (${t.trial}) and position ${brandGeneric} against named competitors rather than abstract “pipeline threats.”`,
)}

${h2('executive-brief', 'Executive brief and market disruption index')}

<table>
<thead><tr><th>Metric parameter</th><th>Value and commercial significance</th></tr></thead>
<tbody>
<tr><td><strong>Compound and mechanism</strong></td><td>${brandGeneric} — ${t.mechanism}</td></tr>
<tr><td><strong>Sponsor</strong></td><td>${t.sponsor}</td></tr>
<tr><td><strong>Indication / target group</strong></td><td>${t.indication}</td></tr>
<tr><td><strong>Global market projection</strong></td><td>${t.marketProjection}</td></tr>
<tr><td><strong>Primary competitors</strong></td><td>${t.competitors.join('; ')}</td></tr>
<tr><td><strong>BioNixus disruption rating</strong></td><td><strong>${t.disruptionRating}</strong> — ${t.regulatoryNote}</td></tr>
</tbody>
</table>

${h2('clinical-profile', 'Clinical profile and data deep dive')}

${p(
  `The evidentiary spine for ${brandGeneric} centers on ${t.trial}. Primary readouts cited at approval or CHMP opinion stage include ${t.primaryData}. Safety governance must reflect class-specific vigilance: ${t.safety}.`,
)}

${p(
  `Commercial teams should benchmark these figures against current standard of care in ${t.therapeuticArea}, not against cross-therapy averages. In Gulf markets, where private insurance step therapy and public tender lists diverge sharply, clinical magnitude only converts to revenue when paired with hospital committee narratives at ${link('/healthcare-market-research/saudi-arabia', 'Saudi Arabia healthcare research')} and ${link('/healthcare-market-research/uae', 'UAE healthcare intelligence')} programs.`,
)}

${h3('Comparator context')}
<ul>
${competitorsList}
${li(`Standard-of-care protocols in Gulf tertiary centers often lag U.S. label expansions by 9–18 months unless sponsors fund medical affairs bridging and ${link('/gcc-hcp-recruitment-market-research', 'GCC HCP panel')} programs.`)}
</ul>

${h2('regulatory-timeline', 'Regulatory timeline and global policy impact')}

${p(
  `${t.actionType} for ${brandGeneric} on ${t.actionDate} fits within a broader 2026 regulatory calendar in which FDA accelerated pathways, PDUFA extensions, and EMA CHMP opinions are reshaping launch sequencing. ${t.regulatoryNote}`,
)}

${p(
  `For U.S. stakeholders, watch advisory committee summaries, label carve-outs, and REMS requirements that influence Gulf dossier assembly. For EU opinions, model European Commission marketing authorization lag (typically 60–90 days) before assuming ex-U.S. reference approvals are quotable in SFDA or MOHAP fast-track files.`,
)}

${h2('market-access-blueprint', 'GCC and EMEA market access blueprint')}

${h3('US and European payer landscapes')}
${p(
  `In the United States, pharmacy benefit managers and specialty tiers will determine near-term uptake for ${brandGeneric}, especially where ${t.therapeuticArea} already has high-cost anchors. Expect prior authorization criteria referencing ${t.trial} endpoints, step therapy through incumbent brands (${t.competitors[0]}), and rebate-heavy contracting if sponsors defend share in crowded classes.`,
)}
${p(
  `European HTA bodies (NICE, G-BA, HAS) will stress incremental cost-effectiveness versus SOC, budget impact in hospital-purchased settings, and risk-sharing where uncertainty remains. Sponsors should pre-build scenario libraries for net price corridors before ex-U.S. list prices leak into Gulf reference baskets.`,
)}

${h3('Saudi Arabia and UAE fast-track registration strategy')}
${p(
  `Sponsors should file via ${link('/sfda-market-access-strategy-saudi-arabia', 'SFDA accelerated registration')} leveraging FDA/EMA approvals, CPP, GMP certificates, and stability modules aligned to ICH expectations. In the UAE, coordinate ${link('/uae-market-access-research', 'MOHAP and DHA/DOH pathways')} when products touch multiple emirates or require hospital device committees.`,
)}
${p(
  `Target 60–90 day registration cycles only when dossiers are pre-harmonized: Arabic labeling, pharmacovigilance responsible person in-region, and tender-ready pharmacoeconomic appendices. BioNixus routinely maps which modules can be recycled from FDA packages versus what Gulf authorities still require de novo (real-world evidence plans, heat-stability for cold-chain biologics, pilgrimage-season adherence assumptions).`,
)}

${h3('NUPCO tender positioning and hospital access')}
${p(
  `Public uptake in Saudi Arabia flows through ${link('/saudi-payer-market-access-research', 'NUPCO centralized procurement')}. Early clinical champions at King Faisal Specialist Hospital & Research Centre (KFSHRC), National Guard Health Affairs (NGHA), and Ministry of Health clusters influence whether a molecule enters award cycles or remains private-sector only.`,
)}
${p(
  `In the UAE, Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, and Hamad Medical Corporation (Qatar) analogues shape private payer medical policies—Thiqa, Daman, Tawuniya, and Bupa Arabia medical policies can move faster than public lists but require photographic prior authorization discipline in dermatology and oncology categories.`,
)}
${p(
  `For ${t.therapeuticArea}, align tender narratives to epidemiology in Gulf cities (obesity, diabetes, oncology throughput, rare disease registries) and quantify budget impact under conservative uptake curves. Cross-link portfolio context via ${link('/gcc-pharma-market-report-2026', 'GCC pharmaceutical market outlook 2026')} and ${link('/healthcare-market-research', 'healthcare market research hub')}.`,
)}

${h2('commercial-competitive', 'Commercial competitive dynamics')}

${p(
  `Launch committees must war-game three reactions: (1) incumbent price defense and rebate expansion; (2) interchangeable biosimilar or next-gen formulation announcements; (3) indication creep from competitors seeking to protect share. For ${brandGeneric}, assess whether ${t.sponsor} will cannibalize its own portfolio or create separate brands by channel (self-pay obesity clinics versus insured hospital formularies).`,
)}
${p(
  `Supply chain and medical affairs intensity matter: cold-chain biologics and cell therapies require different site-of-care training than oral small molecules. If ${brandGeneric} is oral, emphasize adherence and Ramadan dosing counselling in medical affairs; if biologic or gene therapy, prioritize infusion chair throughput and CRS protocols.`,
)}

${h2('bionixus-advisory', 'BioNixus advisory directive')}

${p(
  `To capture value from ${brandGeneric} in GCC and wider MENA, global launch teams should engage regional partners before ex-U.S. list prices anchor unrealistic tender expectations. BioNixus delivers NUPCO tender intelligence, SFDA/MOHAP dossier sequencing, bilingual clinician trackers, and KOL mapping inside flagship centers cited above.`,
)}
${p(
  `Request a commercial launch briefing to align ${t.trial} evidence with payer-ready narratives, competitor simulations, and 90-day registration/tender roadmaps: ${link('/contact', 'Request a Commercial Launch Briefing with BioNixus')}.`,
)}

${h2('faq', 'Frequently asked questions')}

<h3>What did regulators decide for ${brandGeneric} in Q2 2026?</h3>
${p(`${t.sponsor} received ${t.actionType} on ${t.actionDate} for ${brandGeneric} in ${t.indication}. ${t.regulatoryNote}`)}

<h3>Which clinical trials support ${brandGeneric}?</h3>
${p(`Key evidence includes ${t.trial}, with primary outcomes summarized as ${t.primaryData}.`)}

<h3>How should sponsors register ${brandGeneric} in Saudi Arabia and the UAE?</h3>
${p(
  `Leverage FDA/EMA approvals for SFDA and MOHAP fast-track routes, pre-build Arabic labeling, and attach Gulf-specific budget impact models. BioNixus supports ${link('/sfda-market-access-strategy-saudi-arabia', 'SFDA market access strategy')} execution.`,
)}

<h3>Who are the main competitors to ${brandGeneric}?</h3>
${p(`Primary comparators include ${t.competitors.join(', ')}. Differentiation must be proven on endpoints payers recognize, not mechanism slides alone.`)}

<h3>What is the commercial outlook in GCC markets?</h3>
${p(
  `Gulf uptake depends on NUPCO award timing, private insurer PA rules, and KOL adoption at tertiary centers. ${t.marketProjection} globally; regional shares require localized analogues—not EU net price copy/paste.`,
)}

<h3>How can BioNixus help launch teams?</h3>
${p(
  `BioNixus provides ${link('/services/quantitative-research', 'quantitative healthcare research')}, ${link('/services/market-access', 'market access consulting')}, physician panels, and tender analytics across GCC. ${link('/contact', 'Contact BioNixus')} to scope a launch war room.`,
)}
</article>`;
}

export function buildArticleMeta(t) {
  const brandGeneric = `${t.brand} (${t.generic})`;
  const h1 = `${brandGeneric} ${t.actionType} Q2 2026: Commercial Strategy, Clinical Milestones, and GCC Market Access Impact`;
  const metaTitle =
    h1.length > 52 ? `${t.brand} ${t.actionType} 2026 | GCC Access | BioNixus` : `${h1} | BioNixus`;
  const metaDescription = `${t.sponsor} ${t.actionType} for ${t.brand}: ${t.headline.slice(0, 90)}. Clinical, regulatory, NUPCO/SFDA strategy for pharma commercial leaders.`.slice(
    0,
    155,
  );
  return { h1, metaTitle: metaTitle.slice(0, 60), metaDescription, ogTitle: h1.slice(0, 90), ogDescription: metaDescription };
}

export function buildToc() {
  return [
    { heading: 'Executive brief and market disruption index', anchor: 'executive-brief' },
    { heading: 'Clinical profile and data deep dive', anchor: 'clinical-profile' },
    { heading: 'Regulatory timeline and global policy impact', anchor: 'regulatory-timeline' },
    { heading: 'GCC and EMEA market access blueprint', anchor: 'market-access-blueprint' },
    { heading: 'Commercial competitive dynamics', anchor: 'commercial-competitive' },
    { heading: 'BioNixus advisory directive', anchor: 'bionixus-advisory' },
    { heading: 'Frequently asked questions', anchor: 'faq' },
  ];
}

export function buildFaq(t) {
  const brandGeneric = `${t.brand} (${t.generic})`;
  return [
    {
      question: `What did regulators decide for ${brandGeneric} in Q2 2026?`,
      answer: `${t.sponsor} received ${t.actionType} on ${t.actionDate} for ${brandGeneric} in ${t.indication}. ${t.regulatoryNote}`,
    },
    {
      question: `Which clinical trials support ${brandGeneric}?`,
      answer: `Key evidence includes ${t.trial}, with primary outcomes summarized as ${t.primaryData}. Safety monitoring should follow: ${t.safety}.`,
    },
    {
      question: `How should sponsors register ${brandGeneric} in Saudi Arabia and the UAE?`,
      answer:
        'Leverage FDA/EMA approvals for SFDA and MOHAP fast-track routes with Arabic labeling, PV responsible persons, and Gulf budget impact appendices. BioNixus supports SFDA and UAE dossier sequencing.',
    },
    {
      question: `Who are the main competitors to ${brandGeneric}?`,
      answer: `Primary comparators include ${t.competitors.join(', ')}. Tender and PA committees will require head-to-head endpoint narratives.`,
    },
    {
      question: `What is the commercial outlook in GCC markets?`,
      answer: `Uptake depends on NUPCO cycles, private insurer PA rules, and KOL adoption at KFSHRC, NGHA, and Cleveland Clinic Abu Dhabi. Global projection: ${t.marketProjection}.`,
    },
    {
      question: 'How can BioNixus help launch teams?',
      answer:
        'BioNixus provides quantitative and qualitative healthcare research, market access consulting, NUPCO tender intelligence, and physician panel programs across GCC and MENA.',
    },
  ];
}

export function inferCategory(area) {
  if (/oncology|lymphoma|breast|lung|bladder|ovarian|ADC|CAR/i.test(area)) return 'Oncology';
  if (/obesity|metabolic|diabetes|endocrin/i.test(area)) return 'Market Intelligence';
  if (/rare|gene|orphan|APDS|PROS|LAD/i.test(area)) return 'Rare Diseases';
  if (/cardio|hypertension/i.test(area)) return 'Cardiology';
  if (/respiratory|pulmonology|asthma/i.test(area)) return 'Respiratory';
  if (/immunology|dermatology|psoriasis/i.test(area)) return 'Immunology';
  if (/vaccine|infectious|HIV|HDV/i.test(area)) return 'Market Intelligence';
  if (/digital|AI|pathology/i.test(area)) return 'Digital Health';
  if (/biosimilar/i.test(area)) return 'Biosimilars';
  return 'Industry Insights';
}
